ISSN 1674-3865  CN 21-1569/R
主管:国家卫生和计划生育委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

Chinese Pediatrics of Integrated Traditional and Western Medicine ›› 2025, Vol. 17 ›› Issue (4): 313-319.doi: 10.20274/j.cnki.issn.2025.04.007

Previous Articles     Next Articles

Efficacy and follow-up of ultrasound-guided botulinum toxin type A injection for lower limb spasticity in cerebral palsy

Zengquan ZHONG1, Xue JIANG1, Shuangquan SUN2, Yiming LI1, Wei LI1, Xin ZHANG3, Hong LI3, Zhihai LYU1()   

  1. 1.Longgang District Maternity&Child Healthcare Hospital of Shenzhen City(Longgang Maternity and Child Institute of Shantou University Medical College), Shenzhen 518172, China
    2.Harbin Children's Hospital(The Sixth Affiliated Hospital of Harbin Medical University), Harbin 150010,China
    3.Heilongjiang Province Sixth Hospital, Harbin 150026,China
  • Received:2025-02-14 Revised:2025-04-25 Published:2025-08-25 Online:2025-08-25
  • Contact: Zhihai LYU E-mail:13613602038@163.com
  • Supported by:
    The Science and Technology Program of Heilongjiang Provincial Health Commission

Abstract:

Objective To investigate the clinical efficacy of ultrasound-guided botulinum toxin type A(BTX-A) injection combined with conventional rehabilitation training in the treatment of lower limb spasticity in children with cerebral palsy (CP). Methods A total of 69 children with spastic CP who were admitted to Harbin Children's Hospital (The Sixth Affiliated Hospital of HMU) and Longgang District Maternal and Child Health Hospital of Shenzhen between June 2017 and March 2022 were randomized into a control group(n=35) and an observation group(n=34).All participants received a standardized rehabilitation protocol:(1)basic motor function reconstruction (task-oriented training, 30 min/session);(2) soft tissue management (wax therapy at 52-55 ℃, 30 min/session);(3)neuromuscular modulation(low-frequency electrical stimulation at 1 Hz, pulse width 100 ms).The observation group additionally received precise positioning injection: ultrasound-guided BTX-A injection (dilution: 50 IU/mL) was performed at gastrocnemius (4–6 IU/kg), and at soleus, semitendinosus and semimembranosus (1–2 IU/kg) based on disease condition. The systematic treatment lasted for 6 months as a course, and the injection was completed at 0 month after the first assessment. Outcomes were assessed by double-blinded assessment team during the follow-ups at baseline, and after 1, 6, and 12 months of treatment through:(1)dynamic assessment of muscular tension using modified Tardieu scale(MTS) to measure the range of motion at 0°and V3 velocity;(2)progress in motor function using gross motor function measurement(GMFM) to score the dimensions D/E;(3)life participation using functional independence measurement for children(WeeFIM) to make quantitative analysis. Results Both groups showed progressive decrease in MTS scores and gross motor function classification system(GMFCS) levels(P<0.05), and progressive increase in GMFM and WeeFIM scores(P<0.05) after 1, 6, and 12 months of treatment. The observation group demonstrated significantly lower MTS scores(P<0.05) and significantly higher GMFM/WeeFIM scores(P<0.05) than the control group at all post-treatment intervals. Conclusions Ultrasound-guided BTX-A injection is feasible for alleviating lower limb spasticity in children with spastic CP, which effectively improves muscle function, gross motor function, and functional independence, so this combined therapy is worthy of clinical promotion and application.

Key words: Cerebral palsy, Spasticity, Botulinum toxin type A, Gross motor function, Child

CLC Number: